Lorusso L, Hart IK, Giometto B, et al. Immunological features of neurological paraneoplastic syndromes. Int J Immunopathol Pharmacol. 2004 May-Aug. 17(2):135-44. [QxMD MEDLINE Link].
BRAIN WR, DANIEL PM, GREENFIELD JG. Subacute cortical cerebellar degeneration and its relation to carcinoma. J Neurol Neurosurg Psychiatry. 1951 May. 14(2):59-75. [QxMD MEDLINE Link].
Posner JB. Paraneoplastic cerebellar degeneration. Can J Neurol Sci. 1993 May. 20 Suppl 3:S117-22. [QxMD MEDLINE Link].
Zaborowski MP, Spaczynski M, Nowak-Markwitz E, Michalak S. Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol. 2014 Jun 26. [QxMD MEDLINE Link].
Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014 May 22. 123(21):3230-8. [QxMD MEDLINE Link]. [Full Text].
Inuzuka T. Autoantibodies in paraneoplastic neurological syndrome. Am J Med Sci. 2000 Apr. 319(4):217-26. [QxMD MEDLINE Link].
Vernino S. Paraneoplastic cerebellar degeneration. Handb Clin Neurol. 2012. 103:215-23. [QxMD MEDLINE Link].
Bolla L, Palmer RM. Paraneoplastic cerebellar degeneration. Case report and literature review. Arch Intern Med. 1997 Jun 9. 157(11):1258-62. [QxMD MEDLINE Link].
Nath U, Grant R. Neurological paraneoplastic syndromes. J Clin Pathol. 1997 Dec. 50(12):975-80. [QxMD MEDLINE Link].
Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000 Jan. 47(1):9-17. [QxMD MEDLINE Link].
Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev. 1999 Aug 15. 13(16):2087-97. [QxMD MEDLINE Link].
Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000 Sep 12. 55(5):713-5. [QxMD MEDLINE Link].
Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998 Apr. 121 ( Pt 4):561-79. [QxMD MEDLINE Link].
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct. 42(10):1931-7. [QxMD MEDLINE Link].
Finsterer J, Voigtländer T, Grisold W. Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration. J Neurol Sci. 2011 Sep 15. 308(1-2):139-41. [QxMD MEDLINE Link].
Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci. 1998 Nov 26. 161(1):88-90. [QxMD MEDLINE Link].
Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983 Dec. 14(6):609-13. [QxMD MEDLINE Link].
Jaeckle KA, Graus F, Houghton A. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol. 1985 Nov. 18(5):592-600. [QxMD MEDLINE Link].
Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997 Aug. 120 ( Pt 8):1279-300. [QxMD MEDLINE Link].
Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain. 1965 Sep. 88(3):529-83. [QxMD MEDLINE Link].
Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 1985 Apr. 35(4):538-43. [QxMD MEDLINE Link].
Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med. 1986 Jan. 80(1):45-52. [QxMD MEDLINE Link].
Mancuso M, Orsucci D, Bacci A, Caldarazzo Ienco E, Siciliano G. Anti-Ri-associated paraneoplastic cerebellar degeneration. Report of a case and revision of the literature. Arch Ital Biol. 2011 Sep. 149(3):318-22. [QxMD MEDLINE Link].
Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med. 2007 Feb 8. 356(6):612-20. [QxMD MEDLINE Link].
Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014 Oct. 35(10):1038-46. [QxMD MEDLINE Link].
Bhargava A, Bhushan B, Kasundra GM, Shubhakaran K, Pujar GS, Banakar B. Response to abdominal hysterectomy with bilateral salpingo-oophorectomy in postmenopausal woman with anti-yo antibody mediated paraneoplastic cerebellar degeneration. Ann Indian Acad Neurol. 2014 Jul. 17(3):355-7. [QxMD MEDLINE Link]. [Full Text].
Rosenfeld MR, Dalmau J. Current Therapies for Paraneoplastic Neurologic Syndromes. Curr Treat Options Neurol. 2003 Jan. 5(1):69-77. [QxMD MEDLINE Link].
Fu JB, Raj VS, Asher A, Lee J, Guo Y, Konzen BS, et al. Inpatient Rehabilitation Performance of Patients With Paraneoplastic Cerebellar Degeneration. Arch Phys Med Rehabil. 2014 Jul 19. [QxMD MEDLINE Link].
Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol. 2003 Jun. 23(2):215-24. [QxMD MEDLINE Link].
Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch Neurol. 1999 Apr. 56(4):405-8. [QxMD MEDLINE Link].
Darnell RB. The importance of defining the paraneoplastic neurologic disorders. N Engl J Med. 1999 Jun 10. 340(23):1831-3. [QxMD MEDLINE Link].
Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003 Oct 16. 349(16):1543-54. [QxMD MEDLINE Link].
Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug. 75(8):1135-40. [QxMD MEDLINE Link].
Greenlee JE. Cytotoxic T cells in paraneoplastic cerebellar degeneration. Ann Neurol. 2000 Jan. 47(1):4-5. [QxMD MEDLINE Link].
Greenlee JE, Brashear HR, Jaeckle KA, et al. Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up. West J Med. 1992 Feb. 156(2):199-202. [QxMD MEDLINE Link].
Jaeckle KA. Paraneoplastic nervous system syndromes. Curr Opin Oncol. 1996 May. 8(3):204-8. [QxMD MEDLINE Link].
Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov. 56(5):715-9. [QxMD MEDLINE Link].
Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre JY, et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol. 2005 Feb. 71(3):231-6. [QxMD MEDLINE Link].
Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005 Apr 16-22. 365(9468):1406-11. [QxMD MEDLINE Link].
Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti- Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry. 1997 Aug. 63(2):133-6. [QxMD MEDLINE Link].
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Medicine. 1998 Nov. 4 (11):1321-4. [QxMD MEDLINE Link]. [Full Text].
Venkatraman A., Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann. Clin. Transl. Neurol. 2016. 3(8):655-663. [QxMD MEDLINE Link]. [Full Text].
Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Annals of Neurology. 25 Nov 2002. 53(1):21-8. [QxMD MEDLINE Link]. [Full Text].
Hadjivassiliou M., Martindale J., Shanmugarajah P., Grünewald R.A., Sarrigiannis P.G., Beauchamp N., et al. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J. Neurol. Neurosurg. Psychiatry. 2017 Apr. 88 (4):301-309. [QxMD MEDLINE Link]. [Full Text].
Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun. 126:1409-18. [QxMD MEDLINE Link]. [Full Text].
Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000 Jan 6. 342:21-7. [QxMD MEDLINE Link]. [Full Text].
Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology. 1992 Oct. 42 (10):1938-43. [QxMD MEDLINE Link]. [Full Text].
Mitoma H, Manto M, Hampe CS. Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges. Curr Neuropharmacol. 2019. 17 (1):33-58. [QxMD MEDLINE Link]. [Full Text].
Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008. 7(4):327–340. [QxMD MEDLINE Link]. [Full Text].
Ducray F., Demarquay G., Graus F., Decullier E., Antoine J.C., Giometto B., et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur. J. Neurol. 2014. 21(5):731-735. [QxMD MEDLINE Link]. [Full Text].
Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015 Nov. 27(6):489–495. [QxMD MEDLINE Link]. [Full Text].